EP2970306A4 - Substituted 6,5-fused bicyclic heteroaryl compounds - Google Patents

Substituted 6,5-fused bicyclic heteroaryl compounds

Info

Publication number
EP2970306A4
EP2970306A4 EP14763821.7A EP14763821A EP2970306A4 EP 2970306 A4 EP2970306 A4 EP 2970306A4 EP 14763821 A EP14763821 A EP 14763821A EP 2970306 A4 EP2970306 A4 EP 2970306A4
Authority
EP
European Patent Office
Prior art keywords
substituted
bicyclic heteroaryl
fused bicyclic
heteroaryl compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14763821.7A
Other languages
German (de)
French (fr)
Other versions
EP2970306A1 (en
Inventor
John Emmerson Campbell
Kevin Wayne Kuntz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of EP2970306A1 publication Critical patent/EP2970306A1/en
Publication of EP2970306A4 publication Critical patent/EP2970306A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
EP14763821.7A 2013-03-15 2014-03-14 Substituted 6,5-fused bicyclic heteroaryl compounds Withdrawn EP2970306A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798113P 2013-03-15 2013-03-15
US201361856625P 2013-07-19 2013-07-19
PCT/US2014/029285 WO2014144747A1 (en) 2013-03-15 2014-03-14 Substituted 6,5-fused bicyclic heteroaryl compounds

Publications (2)

Publication Number Publication Date
EP2970306A1 EP2970306A1 (en) 2016-01-20
EP2970306A4 true EP2970306A4 (en) 2016-08-03

Family

ID=51537774

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14763821.7A Withdrawn EP2970306A4 (en) 2013-03-15 2014-03-14 Substituted 6,5-fused bicyclic heteroaryl compounds

Country Status (3)

Country Link
US (2) US9776996B2 (en)
EP (1) EP2970306A4 (en)
WO (1) WO2014144747A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013361079B2 (en) * 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
LT3057962T (en) 2013-10-16 2023-12-11 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
US20160303135A1 (en) 2013-12-06 2016-10-20 Epizyme, Inc. Combination therapy for treating cancer
CN106999498B (en) 2014-06-17 2021-06-08 Epizyme股份有限公司 EZH2 inhibitors for the treatment of lymphoma
MX2021007003A (en) 2014-10-16 2022-08-09 Epizyme Inc Method for treating cancer.
KR102338802B1 (en) 2014-11-17 2021-12-14 에피자임, 인코포레이티드 Method for treating cancer
SG11201703880VA (en) 2014-12-23 2017-07-28 Novartis Ag Triazolopyrimidine compounds and uses thereof
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
EP3285773A4 (en) 2015-04-20 2019-04-10 Epizyme, Inc. Combination therapy for treating cancer
CN107635965A (en) 2015-06-10 2018-01-26 Epizyme股份有限公司 For treating the EZH2 inhibitor of lymthoma
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
AU2017211331A1 (en) 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
BR112018076443A2 (en) * 2016-06-20 2019-04-09 Novartis Ag crystalline forms of a triazolopyrimidine compound
ES2798424T3 (en) 2016-06-20 2020-12-11 Novartis Ag Triazolopyridine Compounds and Uses of These
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
US11311524B2 (en) 2017-01-19 2022-04-26 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (en) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド Use of EZH2 inhibitors for treating cancer
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
KR102451529B1 (en) 2018-01-31 2022-10-06 미라티 테라퓨틱스, 인크. PRC2 inhibitor
KR20220066892A (en) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Combination therapy of T cell therapy and Zest homologue 2 enhancer (EH2) inhibitor and related methods
TW202400140A (en) 2022-04-27 2024-01-01 日商第一三共股份有限公司 Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593985A (en) 1994-05-23 1997-01-14 Korea Institute Of Science And Technology Cephalosporin compounds
US5616590A (en) * 1994-06-30 1997-04-01 Ciba-Geigy Corporation Plant microbicides
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
ES2183500T3 (en) 1999-06-04 2003-03-16 Jordanian Pharmaceutical Mfg A NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
JP2010532381A (en) 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds useful as RAF kinase inhibitors
CA2722923C (en) 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US7879873B2 (en) * 2008-09-26 2011-02-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as CCR1 receptor antagonists
WO2010144404A1 (en) * 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Pyridil-triazine inhibitors of hedgehog signaling
RU2561055C2 (en) 2009-08-25 2015-08-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Combined therapy with compositions of taxane nanoparticles and hedgehog inhibitors
FR2951172B1 (en) 2009-10-13 2014-09-26 Pf Medicament PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-CANCER AGENT
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JP6020459B2 (en) * 2011-10-18 2016-11-02 アステラス製薬株式会社 Bicyclic heterocyclic compounds
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP2970306A1 (en) 2016-01-20
US20160024081A1 (en) 2016-01-28
US20180208591A1 (en) 2018-07-26
WO2014144747A1 (en) 2014-09-18
US9776996B2 (en) 2017-10-03

Similar Documents

Publication Publication Date Title
EP2970306A4 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
HK1224312A1 (en) Novel compounds
EP2681216A4 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
EP2958562A4 (en) Antidiabetic bicyclic compounds
GB201311910D0 (en) Novel Compounds
GB201311888D0 (en) Novel compounds
EP2935264A4 (en) 1,4-pyridone bicyclic heteroaryl compounds
AP2015008867A0 (en) 3,4-dihydroisquinolin-2(1h)-yl compounds
HK1212337A1 (en) Substituted 5,6-ring-fused naphthopyran compounds 56--
GB201317363D0 (en) Novel compounds
EP3076959A4 (en) Antidiabetic bicyclic compounds
HRP20170247T1 (en) Bicyclic compounds
HK1216749A1 (en) 1,7-naphthyridine derivatives 17-
GB201318222D0 (en) Novel compounds
GB201314926D0 (en) Novel Compounds
EP3060553A4 (en) Novel compounds
GB201322512D0 (en) Novel compounds
HUE040536T2 (en) Process for the preparation of halogen-n, n-dimethylbenzylamines
GB201320021D0 (en) Novel Compounds
HK1218746A1 (en) Novel compounds
GB201316762D0 (en) Novel compounds
GB201316764D0 (en) Novel compounds
GB201401185D0 (en) Novel compounds
GB201321976D0 (en) Novel compounds
GB201321972D0 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20160630

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 487/04 20060101AFI20160624BHEP

Ipc: A61K 31/4162 20060101ALI20160624BHEP

Ipc: A61P 35/02 20060101ALI20160624BHEP

Ipc: A61K 31/437 20060101ALI20160624BHEP

Ipc: C07D 471/04 20060101ALI20160624BHEP

17Q First examination report despatched

Effective date: 20180220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180904